Cargando…

Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas

Positron emission tomography with (68)Gallium ((68)Ga) labeled inhibitors of fibroblast activation protein ((68)Ga-FAPI-PET) is a promising imaging technique for patients with recurrent pancreatic ductal adenocarcinomas (PDAC). To date, it is not clear if different acquisition timepoints for (68)Ga-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoppner, Jorge, van Genabith, Levin, Hielscher, Thomas, Heger, Ulrike, Sperling, Lucas, Colbatzky, Teresa, Gutjahr, Ewgenija, Lang, Matthias, Pausch, Thomas, Spektor, Anna-Maria, Glatting, Frederik M., Liermann, Jakob, Hackert, Thilo, Kratochwil, Clemens, Giesel, Frederik L., Haberkorn, Uwe, Röhrich, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587145/
https://www.ncbi.nlm.nih.gov/pubmed/37857656
http://dx.doi.org/10.1038/s41598-023-43049-2
_version_ 1785123296006635520
author Hoppner, Jorge
van Genabith, Levin
Hielscher, Thomas
Heger, Ulrike
Sperling, Lucas
Colbatzky, Teresa
Gutjahr, Ewgenija
Lang, Matthias
Pausch, Thomas
Spektor, Anna-Maria
Glatting, Frederik M.
Liermann, Jakob
Hackert, Thilo
Kratochwil, Clemens
Giesel, Frederik L.
Haberkorn, Uwe
Röhrich, Manuel
author_facet Hoppner, Jorge
van Genabith, Levin
Hielscher, Thomas
Heger, Ulrike
Sperling, Lucas
Colbatzky, Teresa
Gutjahr, Ewgenija
Lang, Matthias
Pausch, Thomas
Spektor, Anna-Maria
Glatting, Frederik M.
Liermann, Jakob
Hackert, Thilo
Kratochwil, Clemens
Giesel, Frederik L.
Haberkorn, Uwe
Röhrich, Manuel
author_sort Hoppner, Jorge
collection PubMed
description Positron emission tomography with (68)Gallium ((68)Ga) labeled inhibitors of fibroblast activation protein ((68)Ga-FAPI-PET) is a promising imaging technique for patients with recurrent pancreatic ductal adenocarcinomas (PDAC). To date, it is not clear if different acquisition timepoints for (68)Ga-FAPI-PET may result in comparable imaging information and if repetitive (68)Ga-FAPI-PET imaging may add diagnostic value to single timepoint acquisition for recurrent PDAC. Here we analyzed retrospectively early (20 min p.i.) and late (60 min p.i.) (68)Ga-FAPI-PET imaging using FAPI-46 of 33 patients with possible recurrence of PDAC concerning detection rates and uptake over time of local recurrences, metastases, inflammatory lesions of the pancreas, cholestatic lesions of the liver and reactive tissue. 33 patients with histologically confirmed PDAC after complete or partial resection of the pancreas and possible recurrence were examined by (68)Ga-FAPI-46-PET acquired 20- and 60-min post injection (p.i.) of the radiotracer. FAPI-positive lesions were classified as local recurrences, metastases, inflammatory lesions of the pancreas (ILP), cholestatic lesions of the liver and reactive tissue based on histology, PET- and CT-morphology and clinical information. Lesions were contoured, and standardized uptake values (SUVmax and SUVmean) and target-to-background ratios (TBR) were analyzed for both acquisition timepoints. In total, 152 FAPI-positive lesions (22 local relapses, 47 metastases, 26 inflammatory lesions of the pancreas, 28 reactive tissues, and 29 cholestatic lesions) were detected. Detection rates for the early and late acquisition of (68)Ga-FAPI-46-PET were almost identical except cholestatic lesions, which showed a higher detection rate at early imaging. SUV parameters and TBRs of ILP significantly decreased over time. Cholestatic lesions showed a tendency towards decreasing uptake. All other types of lesions showed relatively stable uptake over time. Early and late acquisition of (68)Ga-FAPI-PET results in comparable imaging information in patients with possible recurrence of PDAC. Two timepoint imaging offers additional diagnostic potential concerning differential diagnoses.
format Online
Article
Text
id pubmed-10587145
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105871452023-10-21 Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas Hoppner, Jorge van Genabith, Levin Hielscher, Thomas Heger, Ulrike Sperling, Lucas Colbatzky, Teresa Gutjahr, Ewgenija Lang, Matthias Pausch, Thomas Spektor, Anna-Maria Glatting, Frederik M. Liermann, Jakob Hackert, Thilo Kratochwil, Clemens Giesel, Frederik L. Haberkorn, Uwe Röhrich, Manuel Sci Rep Article Positron emission tomography with (68)Gallium ((68)Ga) labeled inhibitors of fibroblast activation protein ((68)Ga-FAPI-PET) is a promising imaging technique for patients with recurrent pancreatic ductal adenocarcinomas (PDAC). To date, it is not clear if different acquisition timepoints for (68)Ga-FAPI-PET may result in comparable imaging information and if repetitive (68)Ga-FAPI-PET imaging may add diagnostic value to single timepoint acquisition for recurrent PDAC. Here we analyzed retrospectively early (20 min p.i.) and late (60 min p.i.) (68)Ga-FAPI-PET imaging using FAPI-46 of 33 patients with possible recurrence of PDAC concerning detection rates and uptake over time of local recurrences, metastases, inflammatory lesions of the pancreas, cholestatic lesions of the liver and reactive tissue. 33 patients with histologically confirmed PDAC after complete or partial resection of the pancreas and possible recurrence were examined by (68)Ga-FAPI-46-PET acquired 20- and 60-min post injection (p.i.) of the radiotracer. FAPI-positive lesions were classified as local recurrences, metastases, inflammatory lesions of the pancreas (ILP), cholestatic lesions of the liver and reactive tissue based on histology, PET- and CT-morphology and clinical information. Lesions were contoured, and standardized uptake values (SUVmax and SUVmean) and target-to-background ratios (TBR) were analyzed for both acquisition timepoints. In total, 152 FAPI-positive lesions (22 local relapses, 47 metastases, 26 inflammatory lesions of the pancreas, 28 reactive tissues, and 29 cholestatic lesions) were detected. Detection rates for the early and late acquisition of (68)Ga-FAPI-46-PET were almost identical except cholestatic lesions, which showed a higher detection rate at early imaging. SUV parameters and TBRs of ILP significantly decreased over time. Cholestatic lesions showed a tendency towards decreasing uptake. All other types of lesions showed relatively stable uptake over time. Early and late acquisition of (68)Ga-FAPI-PET results in comparable imaging information in patients with possible recurrence of PDAC. Two timepoint imaging offers additional diagnostic potential concerning differential diagnoses. Nature Publishing Group UK 2023-10-19 /pmc/articles/PMC10587145/ /pubmed/37857656 http://dx.doi.org/10.1038/s41598-023-43049-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hoppner, Jorge
van Genabith, Levin
Hielscher, Thomas
Heger, Ulrike
Sperling, Lucas
Colbatzky, Teresa
Gutjahr, Ewgenija
Lang, Matthias
Pausch, Thomas
Spektor, Anna-Maria
Glatting, Frederik M.
Liermann, Jakob
Hackert, Thilo
Kratochwil, Clemens
Giesel, Frederik L.
Haberkorn, Uwe
Röhrich, Manuel
Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
title Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
title_full Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
title_fullStr Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
title_full_unstemmed Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
title_short Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
title_sort comparison of early and late (68)ga-fapi-46-pet in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587145/
https://www.ncbi.nlm.nih.gov/pubmed/37857656
http://dx.doi.org/10.1038/s41598-023-43049-2
work_keys_str_mv AT hoppnerjorge comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT vangenabithlevin comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT hielscherthomas comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT hegerulrike comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT sperlinglucas comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT colbatzkyteresa comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT gutjahrewgenija comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT langmatthias comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT pauschthomas comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT spektorannamaria comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT glattingfrederikm comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT liermannjakob comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT hackertthilo comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT kratochwilclemens comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT gieselfrederikl comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT haberkornuwe comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas
AT rohrichmanuel comparisonofearlyandlate68gafapi46petin33patientswithpossiblerecurrenceofpancreaticductaladenocarcinomas